{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T01:09:16Z","timestamp":1774314556438,"version":"3.50.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,7]]},"DOI":"10.7759\/cureus.100981","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T10:32:22Z","timestamp":1767781942000},"source":"Crossref","is-referenced-by-count":1,"title":["Progressive Fibrotic Pneumonitis Following Durvalumab Therapy: A Challenging Case"],"prefix":"10.7759","author":[{"given":"Susana","family":"Viana","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Monteiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Vila\u00e7a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In\u00eas","family":"Neves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"Calisto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02528","article-title":"Management of stage III non-small-cell lung cancer: ASCO guideline","volume":"40","author":"Daly ME","year":"2022","unstructured":"Daly ME, Singh N, Ismaila N, et al.. Management of stage III non-small-cell lung cancer: ASCO guideline. J Clin Oncol. 2022, 40:1356-84. 10.1200\/JCO.21.02528","journal-title":"J Clin Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"377","author":"Antonia SJ","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D, et al.. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017, 377:1919-29. 10.1056\/NEJMoa1709937","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2022.02.003","article-title":"Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: a post-hoc analysis of the PACIFIC trial","volume":"166","author":"Naidoo J","year":"2022","unstructured":"Naidoo J, Vansteenkiste JF, Faivre-Finn C, et al.. Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: a post-hoc analysis of the PACIFIC trial. Lung Cancer. 2022, 166:84-93. 10.1016\/j.lungcan.2022.02.003","journal-title":"Lung Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider BJ","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021, 39:4073-126. 10.1200\/JCO.21.01440","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2024.100638","article-title":"Symptomatic pneumonitis with durvalumab after concurrent chemoradiotherapy in unresectable stage III NSCLC","volume":"5","author":"Vansteenkiste JF","year":"2024","unstructured":"Vansteenkiste JF, Naidoo J, Faivre-Finn C, et al.. Symptomatic pneumonitis with durvalumab after concurrent chemoradiotherapy in unresectable stage III NSCLC. JTO Clin Res Rep. 2024, 5:100638. 10.1016\/j.jtocrr.2024.100638","journal-title":"JTO Clin Res Rep"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1103927","article-title":"Efficacy and safety of consolidation durvalumab after chemoradiation therapy for stage III non-small-cell lung cancer: a systematic review, meta-analysis, and meta-regression of real-world studies","volume":"14","author":"Zhang Y","year":"2023","unstructured":"Zhang Y, Tian Y, Zheng L, Sun X, Zhao Z, Zheng Y, Tian J. Efficacy and safety of consolidation durvalumab after chemoradiation therapy for stage III non-small-cell lung cancer: a systematic review, meta-analysis, and meta-regression of real-world studies. Front Pharmacol. 2023, 14:1103927. 10.3389\/fphar.2023.1103927","journal-title":"Front Pharmacol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2023.09.050","article-title":"Pneumonitis after chemoradiotherapy and adjuvant durvalumab in stage III non-small cell lung cancer","volume":"118","author":"Edwards DM","year":"2024","unstructured":"Edwards DM, Sankar K, Alseri A, et al.. Pneumonitis after chemoradiotherapy and adjuvant durvalumab in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2024, 118:963-70. 10.1016\/j.ijrobp.2023.09.050","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2340\/1651-226X.2025.42384","article-title":"Rising incidence of radiation pneumonitis after adjuvant durvalumab in NSCLC patients treated with concurrent chemoradiotherapy","volume":"64","author":"Stoffers RH","year":"2025","unstructured":"Stoffers RH, Niezink AG, Chouvalova O, et al.. Rising incidence of radiation pneumonitis after adjuvant durvalumab in NSCLC patients treated with concurrent chemoradiotherapy. Acta Oncol. 2025, 64:267-75. 10.2340\/1651-226X.2025.42384","journal-title":"Acta Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13900","article-title":"Radiation versus immune checkpoint inhibitor associated pneumonitis: distinct radiologic morphologies","volume":"26","author":"Chen X","year":"2021","unstructured":"Chen X, Sheikh K, Nakajima E, et al.. Radiation versus immune checkpoint inhibitor associated pneumonitis: distinct radiologic morphologies. Oncologist. 2021, 26:e1822-32. 10.1002\/onco.13900","journal-title":"Oncologist"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13240","article-title":"Clinical diagnosis and treatment of immune checkpoint inhibitor-associated pneumonitis","volume":"11","author":"Wang H","year":"2020","unstructured":"Wang H, Guo X, Zhou J, et al.. Clinical diagnosis and treatment of immune checkpoint inhibitor-associated pneumonitis. Thorac Cancer. 2020, 11:191-7. 10.1111\/1759-7714.13240","journal-title":"Thorac Cancer"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1072612","article-title":"Nintedanib in an elderly non-small-cell lung cancer patient with severe steroid-refractory checkpoint inhibitor-related pneumonitis: a case report and literature review","volume":"13","author":"Pan L","year":"2022","unstructured":"Pan L, Meng F, Wang W, et al.. Nintedanib in an elderly non-small-cell lung cancer patient with severe steroid-refractory checkpoint inhibitor-related pneumonitis: a case report and literature review. Front Immunol. 2022, 13:1072612. 10.3389\/fimmu.2022.1072612","journal-title":"Front Immunol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2023.100586","article-title":"Pneumonitis during durvalumab consolidation therapy affects survival in stage III NSCLC","volume":"4","author":"Kinehara Y","year":"2023","unstructured":"Kinehara Y, Shiroyama T, Tamiya A, et al.. Pneumonitis during durvalumab consolidation therapy affects survival in stage III NSCLC. JTO Clin Res Rep. 2023, 4:100586. 10.1016\/j.jtocrr.2023.100586","journal-title":"JTO Clin Res Rep"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-021-01191-6","article-title":"Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer","volume":"40","author":"Nishimura A","year":"2022","unstructured":"Nishimura A, Ono A, Wakuda K, et al.. Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer. Invest New Drugs. 2022, 40:403-10. 10.1007\/s10637-021-01191-6","journal-title":"Invest New Drugs"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1320","article-title":"PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course","volume":"22","author":"Nishino M","year":"2016","unstructured":"Nishino M, Ramaiya NH, Awad MM, et al.. PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course. Clin Cancer Res. 2016, 22:6051-60. 10.1158\/1078-0432.CCR-16-1320","journal-title":"Clin Cancer Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.resinv.2025.02.005","article-title":"Utility of serum Krebs von den Lungen-6 and surfactant protein-D levels for the diagnosis of immune checkpoint inhibitor-induced immune-related pneumonitis","volume":"63","author":"Nakai S","year":"2025","unstructured":"Nakai S, Karayama M, Inoue Y, et al.. Utility of serum Krebs von den Lungen-6 and surfactant protein-D levels for the diagnosis of immune checkpoint inhibitor-induced immune-related pneumonitis. Respir Investig. 2025, 63:259-64. 10.1016\/j.resinv.2025.02.005","journal-title":"Respir Investig"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/449508-progressive-fibrotic-pneumonitis-following-durvalumab-therapy-a-challenging-case","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T10:32:23Z","timestamp":1767781943000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/449508-progressive-fibrotic-pneumonitis-following-durvalumab-therapy-a-challenging-case"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.100981","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,7]]}}}